interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Tecovirimat

Generic competition · all medicines · read 12 November 2026

Is there a generic of Tecovirimat, and who makes it?

Tecovirimat appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Tecovirimat2 dosage-form groups in the Orange Book
0generic makers listed
  1. Tecovirimat appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Tpoxx. No generic is listed as marketed.

2015202020252030203501brand 2018data datePatent 8039504 listed to expire 23 July 2027Patent 9339466 listed to expire 23 March 2031Patent 12433868 listed to expire 23 March 2031Patent 7737168 listed to expire 4 September 2031Patent 11890270 listed to expire 8 August 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 July 2027Patent 8039504 drug product
  • 23 March 2031Patent 9339466 drug substance
  • 23 March 2031Patent 12433868 drug product
  • 4 September 2031Patent 7737168
  • 8 August 2032Patent 11890270

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Tpoxx. No generic is listed as marketed.

202020252030203501brand 2022data datePatent 8039504 listed to expire 23 July 2027Patent 9907859 listed to expire 2 August 2031Patent 10576165 listed to expire 2 August 2031Patent 9233097 listed to expire 2 August 2031Patent 7737168 listed to expire 4 September 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 July 2027Patent 8039504 drug product
  • 2 August 2031Patent 9907859
  • 2 August 2031Patent 10576165 drug product
  • 2 August 2031Patent 9233097 drug product
  • 4 September 2031Patent 7737168

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.